HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Listerine safety/efficacy for plaque, gingivitis claims recommended by FDA subcommittee.

This article was originally published in The Rose Sheet

Executive Summary

LISTERINE SAFETY AND EFFICACY FOR PLAQUE, GINGIVITIS CLAIMS RECOMMENDED by FDA's Dental Products Panel Plaque Subcommittee at its Oct. 29-30 meeting in Gaithersburg, Md. The subcommittee concluded that the active ingredient combination of essential oils in Warner-Lambert's Listerine mouthwash -- .064% thymol, .042% menthol, .092% eucalyptol and .06% menthol salicylate -- should be included in the oral health care products final monograph as a Category I (safe and effective) treatment for plaque and gingivitis.
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS004808

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel